G1SecL05: Difference between revisions
| Line 11: | Line 11: | ||
Vaccine efficiency was evaluated by immunizing mice with LYMErix and using ELISA to measure their serum antibody response to ospA. In 1996, clinical trials conducted in highly endemic areas of the United States with sample size exceeding 10,000 subjects, LYMErix was found to confer protective immunity to ''B. burgdorferi'' in 76% of adults and 100% of children with only mild and transient short term effects<ref name = "epitope"/>. | Vaccine efficiency was evaluated by immunizing mice with LYMErix and using ELISA to measure their serum antibody response to ospA. In 1996, clinical trials conducted in highly endemic areas of the United States with sample size exceeding 10,000 subjects, LYMErix was found to confer protective immunity to ''B. burgdorferi'' in 76% of adults and 100% of children with only mild and transient short term effects<ref name = "epitope"/>. | ||
==Development of the recombinant vaccine== | ===Development of the recombinant vaccine=== | ||
Initial approaches for vaccines to treat lyme disease solely focused on ospA after studies involving passive immunization in mice. Studies indicated that passive immunization in mice only occurred if the blood from humans infected with Lyme disease contained anti-ospA monoclonal antibodies<ref name =<ref name="quantitative"/> . Although ospA vaccines, such as Lymerix, were able to halt transmission of the spirochetes, they were immediately pulled from the market due to chronic side effects such as severe arthritis. Additionally, quantitative analysis of immune response<ref name= "quantitative">PMID:11865439</ref> of the whole ospA indicated that it is not predictive of protection. | Initial approaches for vaccines to treat lyme disease solely focused on ospA after studies involving passive immunization in mice. Studies indicated that passive immunization in mice only occurred if the blood from humans infected with Lyme disease contained anti-ospA monoclonal antibodies<ref name =<ref name="quantitative"/> . Although ospA vaccines, such as Lymerix, were able to halt transmission of the spirochetes, they were immediately pulled from the market due to chronic side effects such as severe arthritis. Additionally, quantitative analysis of immune response<ref name= "quantitative">PMID:11865439</ref> of the whole ospA indicated that it is not predictive of protection. | ||